Tiziana Life Sciences Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.7351
- Today's High:
- $0.75
- Open Price:
- $0.7351
- 52W Low:
- $0.5
- 52W High:
- $1.39
- Prev. Close:
- $0.76
- Volume:
- 62565
Company Statistics
- Market Cap.:
- $75.30 million
- Book Value:
- 0.195
- Revenue TTM:
- $-3595000
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -24.21%
- Return on Equity TTM:
- -50.61%
Company Profile
Tiziana Life Sciences Ltd had its IPO on 2000-03-24 under the ticker symbol TLSA.
The company operates in the Healthcare sector and Biotechnology industry. Tiziana Life Sciences Ltd has a staff strength of 9 employees.
Stock update
Shares of Tiziana Life Sciences Ltd opened at $0.74 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.74 - $0.75, and closed at $0.75.
This is a -1.32% slip from the previous day's closing price.
A total volume of 62,565 shares were traded at the close of the day’s session.
In the last one week, shares of Tiziana Life Sciences Ltd have slipped by -1.32%.
Tiziana Life Sciences Ltd's Key Ratios
Tiziana Life Sciences Ltd has a market cap of $75.30 million, indicating a price to book ratio of 1.4989 and a price to sales ratio of 0.
In the last 12-months Tiziana Life Sciences Ltd’s revenue was $-3595000 with a gross profit of $0 and an EBITDA of $-14585000. The EBITDA ratio measures Tiziana Life Sciences Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Tiziana Life Sciences Ltd’s operating margin was 0% while its return on assets stood at -24.21% with a return of equity of -50.61%.
In Q4, Tiziana Life Sciences Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Tiziana Life Sciences Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.15 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tiziana Life Sciences Ltd’s profitability.
Tiziana Life Sciences Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.7475. Its price to sales ratio in the trailing 12-months stood at 0.
Tiziana Life Sciences Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $26.48 million
- Total Liabilities
- $6.66 million
- Operating Cash Flow
- $75155.00
- Capital Expenditure
- $845
- Dividend Payout Ratio
- 0%
Tiziana Life Sciences Ltd ended 2024 with $26.48 million in total assets and $0 in total liabilities. Its intangible assets were valued at $26.48 million while shareholder equity stood at $19.57 million.
Tiziana Life Sciences Ltd ended 2024 with $0 in deferred long-term liabilities, $6.66 million in other current liabilities, 102000.00 in common stock, $-116263000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.12 million and cash and short-term investments were $18.12 million. The company’s total short-term debt was $122,000 while long-term debt stood at $0.
Tiziana Life Sciences Ltd’s total current assets stands at $24.28 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $5.99 million compared to accounts payable of $4.96 million and inventory worth $0.
In 2024, Tiziana Life Sciences Ltd's operating cash flow was $75155.00 while its capital expenditure stood at $845.
Comparatively, Tiziana Life Sciences Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.75
- 52-Week High
- $1.39
- 52-Week Low
- $0.5
- Analyst Target Price
- $3
Tiziana Life Sciences Ltd stock is currently trading at $0.75 per share. It touched a 52-week high of $1.39 and a 52-week low of $1.39. Analysts tracking the stock have a 12-month average target price of $3.
Its 50-day moving average was $0.69 and 200-day moving average was $0.72 The short ratio stood at 0.1 indicating a short percent outstanding of 0%.
Around 4346.5% of the company’s stock are held by insiders while 106.9% are held by institutions.
Frequently Asked Questions About Tiziana Life Sciences Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.